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SUMMARY 
9 cases of schizophrenia meeting Spitzer's Research Diagnostic Criteria and nonrespondent to con-
ventional treatment were treated with carbamazepine, either alone or in combination with neuroleptics 
and 7 cases had shown improvement. 
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Carbamazepine has been found to be 
useful in the treatment of affective dis-
orders (Okuma et al., 1979; Ballenger 
and Post, 1980; Sethi et al., 1P83) and in 
cases of epilepsy with psychic disturban-
ces like psychopathic behaviour, dysph-
oria and schizophrenia-like psychoses 
(Myrstener, 1968; Helmchen 1976). Car-
bamazepine (CBZ) is a tricyclic com-
pound and its steric structure approaches 
that of psychotropic drugs such as chlor-
promazime, imipramine and maprotiline, 
it may therefore be regarded as one of 
the polycyclic psychoactive drugs (Sill-
anapaa, 1981). It is not clear whether 
CBZ has any therapeutic benefits in 
schizophrenia. 9 cases of schizophrenia 
fulfilling Research Diagnostic Criteria 
(RDC; Spitzer et al, 1978) for definite 
illness, nonrespondent to conventional 
treatment and free from major physical 
illness were chosen for this study. They 
were treated with CBZ either alone or in 
combination with neuroleptics, starting 
from October 1982. Final assessment 
was compiled in September 1983. 
CASE REPORTS 
Patient 1, born 1959, male, onset 
of schizophrenia in 1972, family history 
of psychosis and epilepsy present, had not 
responded to chlorpromazine, triflupera-
zine and haloperidol. EEG normal. 
Had grossly noticeable nystagmus but 
no other neurological abnormality. Ne-
urologists and opthalmologists considered 
it inexplicable and advised review at 
intervals. Had profound thought dis-
order, delusions of persecution and re-
ference and auditory hallucinations. CBZ 
alone was given, starting with 400 mg/ 
day and gradually raised to 1200mg/day. 
Improvement was noticed by 4 weeks 
time and at the end of 2 months of ther-
apy he became asymptomatic and re-
sumed working. Patient was maintai-
ned on the same dose for 3J months 
and he remained well. His nystagmus 
remained same. Patient had not deve-
loped any side effects, except a subjec-
tive sense of physical weakness. Hema-
tological investigations revealed no ab-
normality. Since carbamazepine itself 
is known to cause nystagmus and as the 
patient was maintaining improvement, 
the dosage was gradually decreased to 
400mg/day and symptoms totally rela-
psed. Then a combination of antipsy-
chotics with CBZ 400 mg per day was 
given and patient has improved again. 
Patient 2, male, born 1945, schizo-
phrenic illness commenced in 1968. 
After unsuccessful treatment at several 
psychiatric centres, underwent prefron-
tal leucotomy in 1976. He developed 
fits and was put on phenobarbitone and 
phenytoin sodium in addition to halo-
peridol and was leading a vegetative exis-
tence. CBZ was introduced in place of 
the previous antiepileptics and the do-
sage enhanced to 800mg/day. Patient 
had shown about 50% improvement, 
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which he maintained for 7 months. 
He then developed tubercular pleurisy 
for which antitubercular treatment too 
was prescribed. His condition deteriorat-
ed. CBZ was raised to lOOOmg/day and 
his condition has again improved. 
Patient 3, female,, born 1949, schi-
zophrenic sicne 1978 and patient 4, male, 
born 1953, schizophrenic since 1969, un-
responsive to antipsychotics and electro-
convulsive therapy failed to respond to 
CBZ alone upto 1200mg/day and in com-
bination with antipsychotics. The latter 
patient developed nystagmus, diplopia 
and ataxia when the dosage of CBZ was 
raised to 1200mg/day. 
Patient 5, female, born 1961, schi-
zophrenic since 1978; patient 6, male, 
born 1957, schizophrenic since 1980 and 
patient 7, female, born 1959 schizophre-
nic since 1977 were treated at different 
centers with antipsychotics but with poor 
response. When CBZ was added up-
to 800mg/day to the antipsychotic al-
ready being received paranoid symp-
toms subsided and they regained interest 
in personal and social functioning. 
Their affective responsiveness improved 
considerably. In patient 6, when CBZ 
was withdrawn, symptoms relapsed and 
improved after reinstituting CBZ. 
Patient 8, female, born 1954, onset 
of neurotic-like symptoms in 1978, cul-
minated in schizophrenia in 1980. Sho-
wed poor response to phenothiazines and 
a divorce suit was filed in the court by 
the husband of the patient as she was 
considered mentally unfit. In addition 
to florid schizophrenic symptoms patient 
complained of occasional epigastric dis-
tress with giddiness and hence an EEG 
was done which was normal. Patient 
was put only on CBZ 800/mg day and 
achieved over 90% improvement. 
Patient 9, male, born 1938, schizo-
phrenic illness commenced in 1974, im-
proved with phenothiazines and E.G.T-
Had a relapse in 1981 with marked para-
noid tendencies with no response to 
phenothiazines and was removed from 
his job, following which he manifested 
depressive symptoms in addition. When 
the patient was first seen in our clinic he 
was found to have tardive dyskinesia 
along with schizophrenic and mild de-
pressive symptoms. Small dose of imi-
pramine was added ar.d the psychotic 
symptoms got further aggravated. In 
view of the dyskinetic movements of lips 
and jaw and poor response to phenothi-
azines all drugs weie stopped and he 
was put on CBZ lOOOmg/day with which 
he made a marked improvement. The 
dyskinetic movements were drastically 
reduced. But mild suspiciousness was 
persisting and hence a small dose of 
phenothiazines was added and further 
improvement was noticed. He has again 
resumed working. 
COMMENT 
This is the first report of the use of 
carbamazepine in cases of established 
schizophrenia. It is a preliminary cli-
nical investigation. 7 out of 9 schizo-
phrenics that have failed to respond to 
conventional treatment have improved 
with carbamazepine- either alone or in 
combination with neuroleptics. The 
improvement noted in the latter group 
may raise a doubt whether it was attri-
butable to CBZ or antipsychotics. The 
very fact that these were the cases that 
have not responded previously to much 
higher dosage of the same antipsychotic 
points to a probable synergistic effect of 
CBZ and neuroleptics. Though initi-
ally reported to be beneficial in manic-
depressives, the efficacy of CBZ in nu-
clear schizophrenics was astounding. 
Neuroleptics are effective both in mania 
and schizophrenia, and carbamazepine 
found to be an anti-manic agent seems 
to have antischizophrenic properties as 244  S. S. RAJU 
well. In addition to its efficacy against 
hallucinatory behaviour, paranoid de-
lusions and thought disorder, CBZ has 
caused an improvement in mood in 
some of the withdrawn schizophrenics. It 
may be useful to add CBZ in cases of 
tardive dyskinesia, which might be bene-
ficial in schizophrenia and in dyskinesia 
too, either due to its effects or conse-
quent to reduction of dosage of anti-
psychotic drugs. If there happen to be 
schizophrenics with post-leuctomy se-
quelae, a trial of CBZ seems justified. It 
has not produced parkinsonian symp-
toms in any of our patients and no pro-
minent daytime sedation was evident. 
At higher dosage it produced nystag-
mus, diplopia, and ataxia in one case, 
a subjective sense of weakness in another 
case, but there were no other visible 
side effects. A better tolerance of the 
diug was observed if it was started at a 
smaller dose and then gradually enhan-
ced. In a few cases it had produced ini-
tial worsening of symptoms followed by 
subsequent improvement and treatment 
should be given at least for 6-8 weeks 
before response could be assessed. Fur-
ther controlled clinical trials of CBZ in 
schizophrenia with objective methods of 
evaluation are indicated as the outcome 
of schizophrenia still remains negative in 
many cases despite the introduction of a 
variety of antipsychotic drugs. CBZ is 
said to affect nor-epinephrine, dopamine, 
acetylcholine, electrolyte, cylic nucseotide 
and GABA systems and how exactly it 
helps schizophrenics remains to be seen. 
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